DOCSLIB.ORG

Oak Ridge) Igor Rouzine, Ph.D

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Oak Ridge) Igor Rouzine, Ph.D Biological dither: HIV’s Hardwired Latency Circuit Leor Weinberger, PhD Gladstone Center for Cell Circuitry Depts. of Pharmaceutical Chemistry, Biochemistry and Biophysics University of California, San Francisco Outline 1. HIV’s hardwired latency program: a noise-amplification circuit 2. Post-transcriptional splicing attenuates noise & stabilizes HIV 3. Harnessing noise to control HIV fate Disclosures Leor Weinberger is a co-founder and chair of the SAB of Autonomous Therapeutics Inc. (ATI) Data reported here were not obtained through any commercial funding The Ones Who Deserve the Credit Leor Weinberger, PhD Gladstone Institutes (Virology/Immunology) Dept. of Biochemistry and Biophysics California Inst. for Quantitative Biology (QB3) University of California, San Francisco Single Molecule RNA FISH Stochastic Fluctuations (Noise) in Gene Expression CV Diverse Systems Display Stochastic Fate Commitment HIV Latency Weinberger et al. Cell 2005 Bacterial DNA uptake Suel et al. Science 2007 Stem-cell Reprogramming Chang et al. Nature 2008 Metastasis Gupta et al. Cell 2011 Ab Producing B cells Duffy et al. Science 2012 The HIV Fate Decision Latency driven by active→resting cell transitioning? Latency in < 72h in vivo (resting memory formation ~2wks) (Whitney et al. Nature 2014) Partially penetrant latency reversal upon T-cell activation (Ho et al. Cell 2013) HIV is Not Silenced in Primary Cells during Active-to-Resting Transition Razooky & Pai et al. Cell (2015) Rouzine et al. Cell (2015) HIV is Not Silenced as Primary Cells Relax from Activated to Resting Razooky & Pai et al. Cell (2015) Rouzine et al. Cell (2015) Tat Feedback is Not Silenced in Resting Primary T cells Razooky & Pai et al. Cell (2015) Rouzine et al. Cell (2015) HIV’s Noise-Driven Latency Switch Weinberger et al. Cell (2005) – … – Razooky et al. Cell (2015) Outline 1. HIV’s hardwired latency program: a noise-amplification circuit 2. Post-transcriptional splicing attenuates noise & stabilizes HIV 3. Harnessing noise to control HIV fate If noise drives fate selection, how is fate stabilized? Maike Hansen Hansen et al. Cell 2018 Post-transcriptional splicing mightHIV generate alternative negative splicing feedback Co-transcriptional Splicing No Feedback Hansen et al. Cell 2018 Post-transcriptional splicing mightHIV generate alternative negative splicing feedback Post-transcriptional Splicing Auto-depletion Feedback Hansen et al. Cell 2018 HIV splicing is post-transcriptional US mRNA # mRNA SS mRNA # mRNA MS mRNA # mRNA Single-molecule RNA FISH Hansen et al. Cell 2018 A negative feedback ‘overshoot’ in HIV 1 Early (Nef-GFP) cell Intensity > Intensity cell - Late (mCh-RRE) < Single 0 Time (h) 18 Hansen et al. Cell 2018 Post-transcriptional splicing attenuates noise & stabilizes fate Wild-type HIV-1 Splicing Mutant GFP Time (h) 0h 24h Remove activation 48h GFP Hansen et al. Cell 2018 Outline 1. HIV’s hardwired latency program: a noise-amplification circuit 2. Post-transcriptional splicing attenuates noise & stabilizes HIV 3. Harnessing noise to control HIV fate 85 NoiseScreening Enhancers for Noise Identified (from 1,600 FDA-approved Compounds) mCherry LTR Noise Enhancer Activator mCherry Dar et al. Science (2014) Noise Enhancers Potentiate LRAs (opposite of a stress response) Dar et al. Science (2014) Noise Enhancers Potentiate LRAs in Human Primary CD4+ T Cells with Nina Hosmane & Bob Siliciano Dar et al. Science (2014) Noise Suppressors Attenuate Activators & Stabilize Cell State High-Noise Mutant + Noise Suppressor 0h 24h GFP Hansen et al. Cell 2018 Summary 1. Stochastic noise drives an HIV latency switch 1. Fluctuations can be harnessed Acknowledgements Gladstone/UCSF Cynthia Bolovan-Fritts, Ph.D. Collaborators Anand Pai, Ph.D. Ariel Weinberger (Wyss/Harvard) Noam Vardi, Ph.D. Tom Shenk (Princeton) Winnie Wen, Ph.D. Michael Simpson (Oak Ridge) Igor Rouzine, Ph.D. Michelle Arkin (UCSF) Elena Ingerman, Ph.D. Robert Siliciano (HHMI/Johns Hopkins) Seung-Yong Jung, Ph.D. Sonali Chatuverdi, Ph.D. Elizabeth Tanner, Ph.D. Funding Maike Hansen, Ph.D. Timothy Notton, Ph.D. • NIH Director’s Pioneer Award Ravi Desai • NIH Director’s New Innovator Award Victoria Saykally • NIH Avant-Garde Award for HIV • NIH R01-AI109593, AI09611 Lab Alumni • NIH K25-GM083395 Roy D. Dar, Ph.D. (Faculty, UIUC) • NIH P01AI090935, P50GM081879 Abhyudai Singh, Ph.D. (Faculty, U. Del) • Alfred P. Sloan Research Fellowship Melissa Teng, Ph.D. (A.S.C.) • Pew Scholarship in Biomedical Science Kate Franz (Harvard) • W.M. Keck Research Excellence Award Brandon Razooky, Ph.D. (Rice Lab, Rockefeller) • Bill & Melinda Gates Foundation Luke Rast (Harvard) • California HIV/AIDS Research Program Jon Klein (Yale) • DARPA D15AP0024.
Load more

Recommended publications
  • Collins Challenged Over NCI-Funded Research Linking Tea Party
    Vol. 39 No. 10 March 8, 2013 © Copyright 2013 The Cancer Letter Inc. All rights reserved. Price $405 Per Year. To subscribe, call 800-513-7042 or visit www.cancerletter.com. PO Box 9905 Washington DC 20016 Telephone 202-362-1809 Capitol Hill Collins Challenged Over NCI-Funded Research Capitol Hill Linking Tea Party With Tobacco Companies Collins: "I am quite By Paul Goldberg troubled by this NIH Director Francis Collins told a House subcommittee that he was “troubled” by a paper in which a prominent tobacco control expert, who particular circumstance." is funded by NCI, claims to have found a relationship between tobacco . Page 4 companies and the Tea Party conservative movement. The paper in question appeared in Tobacco Control, a peer-reviewed journal published by British Medical Journal Group. Drawing on documents Sequestration dating back to the 1980s and obtained from tobacco companies, the authors NCI Director Harold point to several instances in which the Tea Party and its predecessor Varmus Seeks to Protect organizations appear to act as proxies for tobacco interests. The paper cites Competitive Awards an NCI grant that supports analysis of tobacco industry documents. Page 5 The paper’s senior author is Stanton Glantz, professor in the Department of Medicine at the University of California San Francisco, a member of the Varmus' Address to Helen Diller Family Comprehensive Cancer Center, and director of the Center for Tobacco Control Research and Education. The NCI Board of (Continued to page 2) Scientific Advisors Sequestration . Page 7 Federal Budget Cuts Enacted March 1; HHS Agencies Grapple with Consequences BSA Approves RFA By Matthew Bin Han Ong Reissuance for the The across-the-board 5.1 percent budget cuts that went into effect March Pediatric Brain 1 slash the NIH budget by $1.553 billion and the NCI budget by $219 million for the remaining fiscal year, officials say.
    [Show full text]
  • Amy Elizabeth Herr
    Amy E. Herr, Ph.D. John D. & Catherine T. MacArthur Professor Bioengineering, University of California, Berkeley UNIVERSITY OF CALIFORNIA, Berkeley, CA 94720 BERKELEY [email protected] | herrlab.berkeley.edu EDUCATION 01/98 – 09/02 STANFORD UNIVERSITY Stanford, CA Doctor of Philosophy, Mechanical Engineering National Science Foundation Graduate Research Fellow “Isoelectric Focusing for Multi-Dimensional Separations in Microfluidic Devices” Advisors: Profs. Thomas W. Kenny & Juan G. Santiago 09/97 – 01/99 STANFORD UNIVERSITY Stanford, CA Master of Science, Mechanical Engineering National Science Foundation Graduate Research Fellow 09/93 – 06/97 CALIFORNIA INSTITUTE OF TECHNOLOGY (CALTECH) Pasadena, CA Bachelor of Science, Engineering & Applied Science with Honors APPOINTMENTS 07/19 – now JOHN D. & CATHERINE T. MACARTHUR PROFESSOR, UNIVERSITY OF CALIFORNIA, BERKELEY 07/14 – 07/19 LESTER JOHN & LYNNE DEWAR LLOYD DISTINGUISHED PROFESSOR (5-year appointment), UC BERKELEY 07/12 – 07/15 ASSOCIATE PROFESSOR, BIOENGINEERING, UNIVERSITY OF CALIFORNIA, BERKELEY 07/07 – 07/12 ASSISTANT PROFESSOR, BIOENGINEERING, UNIVERSITY OF CALIFORNIA, BERKELEY UC BERKELEY/UCSF GRADUATE GROUP IN BIOENGINEERING Directing a research group focused on design and study of microanalytical tools and methods that exploit scale-dependent physics & chemistry to address questions in the biosciences and biomedicine. Chan Zuckerberg Biohub Investigator (2017-21), National Advisory Council for Biomedical Imaging and Bioengineering (2020-23), Faculty Director of Bakar Faculty Fellows Program (2016-now), Co-Convener of Chancellor’s Advisory Committee on Life Sciences (2019-22), BioE Vice-chair for Engagement (2016- now), Director’s Council for Jacobs Institute of Design Innovation, Board Member of Chemical & Biological Microsystems Society (2013-19; Awards Chair 2016-18), Director of Bioengineering Immersion Experience (2012-22; NIH R25).
    [Show full text]
  • Patrick J. H. Bradley
    (415) 734-2745 Patrick J. H. Bradley Gladstone Institutes, GIDB [email protected] 1650 Owens Street Pronouns: he/him/his Bioinformatics Fellow San Francisco, CA 94158 Current Position ······················································································· 2013— J. David Gladstone Institutes at UCSF Bioinformatics Fellow, Prof. Katherine S. Pollard Lab Academic History ····················································································· 2012—13 Lewis-Sigler Institute for Integrative Genomics, Princeton University Postdoctoral Fellow, Prof. Olga G. Troyanskaya Lab 2005—12 Dept. of Molecular Biology, Princeton University Ph.D. in Molecular Biology, Specialization in Quantitative and Computational Biology Thesis: Inferring Metabolic Regulation from High-Throughput Data Advisors: Prof. Joshua D. Rabinowitz, Prof. Olga G. Troyanskaya Committee: Prof. Ned S. Wingreen, Prof. David Botstein 2005 Dept. of Biology, Harvard College A.B. in Biology Peer-Reviewed Publications ·········································································· 1. Patrick H. Bradley, Katherine S. Pollard. “phylogenize: correcting for phylogeny reveals genes associated with microbial distributions.” Bioinformatics, 2019; btz722.∗;z 2. Patrick H. Bradley, Patrick A. Gibney, David Botstein, Olga G. Troyanskaya, Joshua D. Rabinowitz. “Minor isozymes tailor yeast metabolism to carbon availability.” mSystems, 2019; 4:e00170-18.∗;y 3. Patrick H. Bradley, Stephen Nayfach, Katherine S. Pollard. “Phylogeny-corrected identification
    [Show full text]
  • Research Grants
    RESEARCH GRANTS 1 HDF RESEARCH GRANTS We like the philosophy of the Hereditary Disease Foundation that monies raised go directly to support research and that scientists from around the world “are encouraged to collaborate and share their work. “ We’ve devoted ourselves to being supporters and research partners, and we have not been disappointed. The research is vibrant with possibilities. Sandy Fox Member, Board of Directors Hereditary Disease Foundation 1 HDF RESEARCH GRANTS Osama Al-Dalahmah, MD, DPhil Anna Pluciennik, PhD Columbia University, New York, NY Thomas Jefferson University, Philadelphia, PA Cheryl Arrowsmith, PhD Paul Ranum, PhD University of Toronto, Canada Children’s Hospital of Philadelphia, PA Anne Ast, PhD Piere Rodriguez-Aliaga, PhD Max Delbrück Center for Molecular Medicine Stanford University, Palo Alto, CA Berlin, Germany Jennie C. L. Roy, PhD Kristina Becanovic, PhD Massachusetts General Hospital Karolinska Institutet, Stockholm, Sweden Harvard Medical School, Boston, MA Abdellatif Benraiss, PhD David M. Sabatini, MD, PhD University of Rochester, Rochester, NY Whitehead Institute for Biomedical Research Massachusetts Institute of Technology, Cambridge, MA Veronica Ines Brito, PhD University of Barcelona Charlene Smith-Geater, PhD Instituto de Neurosciencias, Spain University of California, Irvine, CA Lauren Byrne, PhD Joan Steffan, PhD University College London (UCL), England University of California, Irvine, CA Amit Laxmikant Deshmukh, PhD Xiao Sun, PhD The Hospital for Sick Children, Toronto, Canada Southwestern Medical Center, Dallas, TX Steven Finkbeiner, MD, PhD Leslie Thompson, PhD Gladstone Institutes University of California, Irvine, CA University of California, San Francisco, CA Nicholas Todd, PhD Brent Fitzwalter, PhD Brigham and Women’s Hospital Broad Institute of MIT and Harvard, Cambridge, MA Harvard Medical School, Boston, MA Ali Khoshnan, PhD Ray Truant, PhD California Institute of Technology, Pasadena, CA McMaster University, Ontario, Canada Ryan Lim, PhD Jean Paul G.
    [Show full text]
  • Real-Time Predictions of Reservoir Size and Rebound Time During Antiretroviral Therapy Interruption Trials for HIV
    RESEARCH ARTICLE Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV Alison L. Hill1*, Daniel I. S. Rosenbloom2, Edward Goldstein3, Emily Hanhauser4, Daniel R. Kuritzkes4, Robert F. Siliciano5☯‡, Timothy J. Henrich6☯‡ 1 Program for Evolutionary Dynamics, Department of Mathematics, Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, Massachusetts, United States of America, 2 Department of Biomedical Informatics, Columbia University Medical Center, New York, New York, United States of America, 3 Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States of America, 4 Division of Infectious Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America, 5 Department of Medicine, Johns Hopkins University School of Medicine and Howard Hughes Medical Institute, Baltimore, Maryland, United States of America, 6 Division of Experimental Medicine, Department of Medicine, University of California, San Francisco, California, United States of America ☯ These authors contributed equally to this work. OPEN ACCESS ‡These authors are joint senior authors on this work. * [email protected] Citation: Hill AL, Rosenbloom DIS, Goldstein E, Hanhauser E, Kuritzkes DR, Siliciano RF, et al. (2016) Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Abstract Interruption Trials for HIV. PLoS Pathog 12(4): e1005535. doi:10.1371/journal.ppat.1005535 Monitoring the efficacy of novel reservoir-reducing treatments for HIV is challenging. The Editor: Leor Weinberger, Gladstone Institute (UCSF), limited ability to sample and quantify latent infection means that supervised antiretroviral UNITED STATES therapy (ART) interruption studies are generally required.
    [Show full text]
  • A Minimal Fate-Selection Switch
    Available online at www.sciencedirect.com ScienceDirect A minimal fate-selection switch Leor S Weinberger To preserve fitness in unpredictable, fluctuating environments, allowing chance to govern each seed’s fate to germinate or a range of biological systems probabilistically generate variant not. For example, if husk thickness of each seed is phenotypes — a process often referred to as ‘bet-hedging’, allowed to stochastically vary, a fraction of seeds will after the financial practice of diversifying assets to minimize risk randomly remain non-germinated regardless of the envi- in volatile markets. The molecular mechanisms enabling bet- ronment, leaving a long-lived sub-population to avoid hedging have remained elusive. Here, we review how HIV extinction during long-term droughts. Borrowing from makes a bet-hedging decision between active replication and economic theory, Cohen proposed that biological organ- proviral latency, a long-lived dormant state that is the chief isms could ‘hedge their bets’ in much the same way that barrier to an HIV cure. The discovery of a virus-encoded bet- financial houses diversify their assets — between higher- hedging circuit in HIV revealed an ancient evolutionary role for risk (higher-yield) stocks and lower-risk (lower-yield) latency and identified core regulatory principles, such as securities — in order to minimize risk against market feedback and stochastic ‘noise’, that enable cell-fate crashes. decisions. These core principles were later extended to fate selection in stem cells and cancer, exposed new therapeutic Stochastic gene expression enables ‘bet- targets for HIV, and led to a potentially broad strategy of using hedging’: from theory to the initial HIV ‘noise modulation’ to redirect cell fate.
    [Show full text]
  • Preexposure Prophylaxis for HIV Infection Integrated with Municipal- and Community-Based Sexual Health Services
    Research Original Investigation Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services Albert Y. Liu, MD, MPH; Stephanie E. Cohen, MD, MPH; Eric Vittinghoff, PhD; Peter L. Anderson, PharmD; Susanne Doblecki-Lewis, MD; Oliver Bacon, MD, MPH; Wairimu Chege, MD, MPH; Brian S. Postle, BS; Tim Matheson, PhD; K. Rivet Amico, PhD; Teri Liegler, PhD; M. Keith Rawlings, MD; Nikole Trainor, MPH; Robert Wilder Blue, MSW; Yannine Estrada, PhD; Megan E. Coleman, FNP; Gabriel Cardenas, MPH; Daniel J. Feaster, PhD; Robert Grant, MD, MPH; Susan S. Philip, MD, MPH; Richard Elion, MD; Susan Buchbinder, MD; Michael A. Kolber, PhD, MD Invited Commentary page 85 IMPORTANCE Several randomized clinical trials have demonstrated the efficacy of Supplemental content at preexposure prophylaxis (PrEP) in preventing human immunodeficiency virus (HIV) jamainternalmedicine.com acquisition. Little is known about adherence to the regimen, sexual practices, and overall effectiveness when PrEP is implemented in clinics that treat sexually transmitted infections (STIs) and community-based clinics serving men who have sex with men (MSM). OBJECTIVE To assess PrEP adherence, sexual behaviors, and the incidence of STIs and HIV infection in a cohort of MSM and transgender women initiating PrEP in the United States. DESIGN, SETTING, AND PARTICIPANTS Demonstration project conducted from October 1, 2012, through February 10, 2015 (last date of follow-up), among 557 MSM and transgender women in 2 STI clinics in San Francisco, California, and Miami, Florida, and a community health center in Washington, DC. Data were analyzed from December 18, 2014, through August 8, 2015. INTERVENTIONS A combination of daily, oral tenofovir disoproxil fumarate and emtricitabine was provided free of charge for 48 weeks.
    [Show full text]
  • Clinical Efficacy and Increased Donor Strain Engraftment After Antibiotic
    medRxiv preprint doi: https://doi.org/10.1101/2021.08.07.21261556; this version posted August 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Clinical efficacy and increased donor strain engraftment after antibiotic pretreatment in a randomized trial of ulcerative colitis patients receiving fecal microbiota transplant Byron J. Smith A,B (ORCID: 0000-0002-0182-404X) Yvette Piceno C (ORCID: 0000-0002-7915-4699) Martin Zydek D Bing Zhang D (ORCID: 0000-0002-3377-0963) Lara Aboud Syriani E Jonathan P. Terdiman D Zain Kassam F Averil Ma G (ORCID: 0000-0003-4817-1258) Susan V. Lynch D,H (ORCID: 0000-0001-5695-7336) Katherine S. Pollard A,B,I,* (ORCID: 0000-0002-9870-6196) Najwa El-Nachef D,* A The Gladstone Institute of Datascience and Biotechnology, San Francisco, CA B Department of Epidemiology and Biostatistics, University of California, San Francisco, CA C Symbiome, Inc., San Francisco, CA D Division of Gastroenterology, University of California, San Francisco, CA E College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA F Finch Therapeutics, Somerville, MA G Department of Medicine, University of California, San Francisco, CA H Benioff Center for Microbiome Medicine, University of California, San Francisco, CA I Chan-Zuckerberg Biohub, San Francisco, CA * Corresponding authors: [email protected] [email protected] NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
    [Show full text]
  • Non-Confidential Report.Pdf
    2009 Annual Report I. Table of Contents Pages Cover 1 Table of Contents 2 Overview of the Activities of the Taube-Koret Center for HD Research 3–5 Oversight of the Taube-Koret Center for HD Research Biographies of our Advisors 6 Report from Dr. Pagno Paganetti 7–10 Report from Dr. Norbert Bischofberger 11–13 Publications and Presentations of the Taube-Koret Center for HD Research Bibliography of Publications 14 HD-related Academic Seminars 15 HD-related Industry Consultations and Seminars 16 Taube-Koret Center for HD Research and the Community Press releases 17–22 News stories 23–33 The Taube-Koret Center for HD Research and 34 HD Families Appendix of Publications 35–113 2 II. Overview of the Activities of the Taube-Koret Center for Huntington’s Disease Research for 2009 We are pleased to provide this annual report describing the activities of the Taube-Koret Center for Huntington’s Disease Research during 2009. The Center was established in 2009 with a joint gift from Taube Philanthropies and the Koret Foundation. It has been a very exciting year. I am delighted to say that we exceeded all five of the scientific and financial goals we set for the first year of operation. Our progress in each area is described in detail below. Goal 1. Establish the Taube-Koret Center for Huntington’s Disease Our initial goal was to establish a Center focused on developing therapeutics for Huntington’s disease (HD). We proposed to develop an infrastructure that would be capable of identifying and validating drug targets for HD and of discovering compounds that modify HD and have the potential to become drugs.
    [Show full text]
  • Millie Hughes-Fulford: Scientist in Space
    Millie Hughes-Fulford: Scientist in Space A resource for using QUEST video in the classroom Watch it online http://science.kqed.org/quest/video/millie-hughes-fulford-scientist-in-space/ | 9:59 minutes QUEST SUBJECTS PROGRAM NOTES NASA’s space program became a celebrated endeavor during the successful Moon Life Biology landing in 1969, but few people link NASA and medical research. At the inception of Science Health NASA’s Apollo Program in the 1960s, scientists discovered a link between gravity and Environment human health. As the government space program drew to an end in 2011, we visited former astronaut Millie Hughes-Fulford, the first woman to travel into space as a working Earth Geology scientist. She conducts experiments in space to further medical understanding. Science Climate Weather In this segment you’ll find… Astronomy .Physical Physics ۞ information on medical experiments done in space Science Chemistry Engineering ۞ a description of the immune system and the importance of T cells. an explanation of gravity’s influence on the human ۞ NEXT immune system. GENERATION SCIENCE STANDARDS TOPIC BACKGROUND High School At the time of first Apollo space missions, in the 1960s, half the astronauts became ill Disciplinary Core Ideas during their flight or soon after coming home. Scientists realized that the pull of Earth’s LS1.A: Structure and gravity helped keep the human body healthy. In a zero gravity environment, the human Function body experiences alterations at the cellular level that can lead to changes in muscle ESS1.B Earth and the Solar tissue, bone loss and problems in the immune system.
    [Show full text]
  • IHV2019 Progress in HIV/AIDS: Challenges in 2020 1 Contents
    IHV2019 Progress in HIV/AIDS: Challenges in 2020 1 Contents CONTENTS Click on any content title to link to that section. 03 Program Information and Acknowledgements 14 Events Schedule 16 Speaker Index 20 Abstract Index 22 Poster Index IHV2019 Progress in HIV/AIDS: Challenges in 2020 2 Welcome IHV2019: 21st Annual International Meeting of the Institute of Human Virology Dear Colleagues and Friends, You are invited to join us on Thursday, October 3 and Friday, October 4 for IHV2019, “Progress in HIV/AIDS: Challenges in 2020.” On Day 1, this year’s meeting will focus on Zero Transmission with sessions on DHHS Responses to HIV/AIDS Epidemic; HIV/AIDS Prevention Strategies; and HIV/AIDS Epidemiology. Day 2 will focus on Opioid Intersection and include sessions on Epidemiology of the HIV-Opioid Intersection and Closing the Gap. Early stage investigators have been invited to submit research abstracts for poster presentation during our poster session on Thursday evening. This year’s meeting will honor Warner C. Green, MD, PhD, as IHV Lifetime Achievement Awardee for Scientifc Contributions. Dr. Greene, who is Director of the Gladstone Center for HIV Cure Research, is most known for his groundbreaking research studies on human retroviruses beginning with HTLV-1 and then on to HIV, as well as the founding and Emeritus Director of the Gladstone Institute of Virology and Immunology. We will also honor IHV Lifetime Achievement Awardees for Public Service, The Honorable Parris Glendening, former Maryland Governor and The Honorable Kathleen Kennedy Townsend, former Maryland Lieutenant Governor. In 1996, both were instrumental in establishing the Institute of Human Virology and have remained strong advocates of its research and clinical efforts since its inception.
    [Show full text]
  • List of Active Members by Class
    MEMBERS List of Active Members by Class October 31, 2017 The list of Academy Members is divided into two categories: Fellows and International Honorary Members. In each category, the Members are arranged by Class and Section. The number after each name indicates the year of election. The symbol * designates Members elected in 2017. An alphabetical index of Members in both categories begins on page 211. FELLOWS – 4,980 i:1 i:1 i:1 Bertozzi, Andrea Louise ’10 Cheeger, Jeff ’06 Engquist, Björn ’15 University of California, Courant Institute of Mathematical University of Texas at Austin Class I–1,246 Los Angeles Sciences, New York University Eskin, Alex ’11 Mathematical and *Bhargava, Manjul ’17 Chernoff, Herman ’74 University of Chicago Princeton University Harvard University Etingof, Pavel ’16 Physical Sciences Bickel, Peter J. ’86 Chorin, Alexandre Joel ’91 Massachusetts Institute University of California, Berkeley University of California, Berkeley of Technology I:1–Mathematics, Birman, Joan S.L. ’12 Christ, F. Michael ’07 Evans, Lawrence Craig ’03 Barnard College University of California, Berkeley University of California, Berkeley Applied Mathematics, Bloch, Spencer Janney ’09 Christodoulou, Demetrios ’01 Fefferman, Charles Louis ’72 and Statistics–219 University of Chicago Eidgenössische Technische Princeton University Bombieri, Enrico ’79 Hochschule Zürich, Switzerland Fefferman, Robert A. ’09 *Aizenman, Michael ’17 Institute for Advanced Study, Colding, Tobias ’08 University of Chicago Princeton University Princeton, NJ Massachusetts Institute Fleming, Wendell Helms ’95 Aldous, David ’04 Borcherds, Richard Ewen ’00 of Technology Brown University University of California, Berkeley University of California, Berkeley Constantin, Peter S. ’10 Frenkel, Edward ’14 Andrews, George E.
    [Show full text]